<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KAYEXALATE- sodium polystyrene sulfonate powder, for suspension </strong><br>Covis Pharmaceuticals, Inc.<br></p></div>
<h1>Kayexalate<span class="Sup">® </span><br>SODIUM POLYSTYRENE SULFONATE, USP <br>Cation-Exchange Resin</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_46cbbd12-d434-4911-9763-a0b943bb4e7a"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">KAYEXALATE, brand of sodium polystyrene sulfonate is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7808d28-9d96-4dde-81bc-5c8357cba004&amp;name=40362e20-dfbf-4367-aae4-49b6292c57d6-01.jpg"></div>
<p>The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an <span class="Italics">in vitro</span> exchange capacity of approximately 3.1 mEq (<span class="Italics">in vivo</span> approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or in an enema.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f4e2917f-8c59-4e92-bc11-eb6f172fe0c1"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. For the most part, this action occurs in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable. It commonly approximates the order of 33 percent but the range is so large that definitive indices of electrolyte balance must be clearly monitored.</p>
<p>Metabolic data are unavailable.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_d4f72d6e-0817-443f-a009-e96f226f042f"></a><a name="section-3"></a><p></p>
<h1>INDICATION AND USAGE</h1>
<p class="First">KAYEXALATE is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_d36f1267-e59f-4429-bcef-cb235432875d"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">KAYEXALATE is contraindicated in the following conditions: patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see <a href="#i4i_precautions_id_cd5a7ee2-e996-4ec5-95a5-587ee202bc35">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_cc171713-6d46-484d-ad83-f0b7d8e0f8c9"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_088a9630-d675-48af-8aa3-e3d6580617f4"></a><a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">Intestinal Necrosis</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">intestinal necrosis</span>, which may be fatal, and other serious gastrointestinal adverse events (<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>, perforation) have been reported in association with KAYEXALATE use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span>, history of intestinal disease or surgery, <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and failure. Concomitant administration of sorbitol is not recommended (see <a href="#i4i_interactions_id_cb90a1eb-2466-40c8-a431-3573e831dcad">PRECAUTIONS, Drug Interactions</a>).</p>
<ul>
<li>Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.</li>
<li>Avoid use in patients who are at risk for developing <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or impaction (including those with history of impaction, chronic <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>, vascular intestinal <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">atherosclerosis</span>, previous bowel resection, or <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>).</li>
<li>Discontinue use in patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca740330-b9a4-46e4-93c0-4c48c1e5151e"></a><a name="section-5.2"></a><p></p>
<h2>Alternative Therapy in Severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">Since effective lowering of serum potassium with KAYEXALATE may take hours to days, treatment with this drug alone may be insufficient to rapidly correct severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> associated with states of rapid tissue breakdown (e.g., <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span> and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>) or <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> so marked as to constitute a medical emergency. Therefore, other definitive measures, including dialysis, should always be considered and may be imperative.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c90782b2-7a7f-4a64-835d-1bb3246801a1"></a><a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">potassium deficiency</span> can occur from therapy with KAYEXALATE. The effect must be carefully controlled by frequent serum potassium determinations within each 24 hour period. Since intracellular <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">potassium deficiency</span> is not always reflected by serum potassium levels, the level at which treatment with KAYEXALATE should be discontinued must be determined individually for each patient. Important aids in making this determination are the patient's clinical condition and electrocardiogram. Early clinical signs of severe <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> include a pattern of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritable</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and delayed thought processes.</p>
<p>Electrocardiographically, severe <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> is often associated with a lengthened Q-T interval, widening, flattening, or inversion of the T wave, and prominent U waves. Also, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur, such as premature atrial, nodal, and ventricular contractions, and supraventricular and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardias</span>. The toxic effects of digitalis are likely to be exaggerated. Marked <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> can also be manifested by severe <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, at times extending into frank <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13476a02-bcca-418b-8e7c-08b1062cd55d"></a><a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span></h2>
<p class="First">Like all cation-exchange resins, KAYEXALATE is not totally selective (for potassium) in its actions, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Accordingly, patients receiving KAYEXALATE should be monitored for all applicable <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e36fb79-288a-441a-b965-8860c2381f21"></a><a name="section-5.5"></a><p></p>
<h2>Systemic <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">Alkalosis</span></h2>
<p class="First">Systemic <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> has been reported after cation-exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with KAYEXALATE. One case of <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizure</span> has been reported in a patient with chronic <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> who was given KAYEXALATE with magnesium hydroxide as laxative. (See <a href="#i4i_interactions_id_cb90a1eb-2466-40c8-a431-3573e831dcad">PRECAUTIONS, Drug Interactions</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_cd5a7ee2-e996-4ec5-95a5-587ee202bc35"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Caution is advised when KAYEXALATE is administered to patients who cannot tolerate even a small increase in sodium loads (i.e., severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or marked <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). In such instances compensatory restriction of sodium intake from other sources may be indicated.</p>
<p>In the event of clinically significant <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, treatment with KAYEXALATE should be discontinued until normal bowel motion is resumed (see <a href="#i4i_section_id_088a9630-d675-48af-8aa3-e3d6580617f4">WARNINGS, <span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">Intestinal Necrosis</span></a>).</p>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_cb90a1eb-2466-40c8-a431-3573e831dcad"></a><a name="section-6.1"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fe8ae14-b21a-4304-bbcc-89edb68ce0e6"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Antacids</span></p>
<p>The simultaneous oral administration of KAYEXALATE with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb109136-5f4c-430d-9cec-f1467faa0da8"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Non-absorbable cation-donating antacids and laxatives</span></p>
<p>Systemic <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> has been reported after cation-exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with KAYEXALATE. One case of <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizure</span> has been reported in a patient with chronic <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> who was given KAYEXALATE with magnesium hydroxide as a laxative.</p>
<p><span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal obstruction</span> due to concretions of aluminum hydroxide when used in combination with KAYEXALATE has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d748bdc-2f52-44e5-91be-80e3a9e21641"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Digitalis</span></p>
<p>The toxic effects of digitalis on the heart, especially various <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> and A-V nodal dissociation, are likely to be exaggerated by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, even in the face of serum digoxin concentrations in the "normal range". (See <a href="#i4i_warnings_id_cc171713-6d46-484d-ad83-f0b7d8e0f8c9">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_989760ed-f835-41f1-be50-d8ae9b7141d6"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold">Sorbitol</span></p>
<p>Concomitant use of Sorbitol with KAYEXALATE has been implicated in cases of <span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">intestinal necrosis</span>, which may be fatal. Therefore, concomitant administration is not recommended. (See <a href="#i4i_warnings_id_cc171713-6d46-484d-ad83-f0b7d8e0f8c9">WARNINGS</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d64f578-fbe5-4dfc-8442-c29a51f910da"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold">Lithium</span></p>
<p>KAYEXALATE may decrease absorption of lithium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ad50a64c-67b3-4f00-b703-42d7fab524ee"></a><a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Bold">Thyroxine</span></p>
<p>KAYEXALATE may decrease absorption of thyroxine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4a812d3a-84f3-4f23-b1f4-ef5b15737793"></a><a name="section-6.2"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b227d084-727f-45ac-91b2-f96fcf529228"></a><a name="section-6.3"></a><p></p>
<h2>Pregnancy Category C</h2>
<p class="First">Animal reproduction studies have not been conducted with KAYEXALATE. It is also not known whether KAYEXALATE can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. KAYEXALATE should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_20e83d20-3f1e-463b-865a-fff8cae5c797"></a><a name="section-6.4"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when KAYEXALATE is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_8cb9a8f0-3760-415a-a03a-a7cee5e3fbd3"></a><a name="section-6.5"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The effectiveness of KAYEXALATE in pediatric patients has not been established. In neonates, KAYEXALATE should not be given by the oral route. In both children and neonates particular care should be observed with rectal administration, as excessive dosage or inadequate dilution could result in impaction of the resin.</p>
<p>Due to the risk of digestive <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> or <span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">intestinal necrosis</span>, particular care should be observed in premature infants or low birth weight infants.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c2036652-0204-4011-a590-32df214895af"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">KAYEXALATE may cause some degree of <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>. <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> may occur especially if high doses are given. Also, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span> and significant <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>, and their related clinical manifestations, may occur (see <a href="#i4i_warnings_id_cc171713-6d46-484d-ad83-f0b7d8e0f8c9">WARNINGS</a>). Occasionally <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> develops. Large doses in elderly individuals may cause <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span> (see <a href="#i4i_precautions_id_cd5a7ee2-e996-4ec5-95a5-587ee202bc35">PRECAUTIONS</a>). Rare instances of <span class="product-label-link" type="condition" conceptid="4342645" conceptname="Gastric necrosis">intestinal necrosis</span> have been reported. <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Intestinal obstruction</span> due to concretions of aluminum hydroxide, when used in combination with KAYEXALATE, has been reported.</p>
<p>The following events have been reported from worldwide post marketing experience:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">Fecal impaction</span> following rectal administration, particularly in children;</li>
<li>Gastrointestinal concretions (<span class="product-label-link" type="condition" conceptid="4198551" conceptname="Bezoar">bezoars</span>) following oral administration;</li>
<li><span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">Ischemic colitis</span>, gastrointestinal tract ulceration or <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> which could lead to <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span>; and,</li>
<li>Rare cases of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute bronchitis</span> and/or broncho-<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> associated with inhalation of particles of polystyrene sulfonate.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_76a327d0-53a0-462f-b41d-59a51d0340be"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage may result in <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> including <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, and <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>. Biochemical disturbances resulting from overdosage may give rise to clinical signs and symptoms of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, including: <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, delayed thought processes, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">hyporeflexia</span>, which may progress to frank <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and/or <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">Tetany</span> may occur. Electrocardiographic changes may be consistent with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> or <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>; <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_d9f2f00f-4713-46ba-9fc7-cd6a67350d78"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Suspension of this drug should be freshly prepared and not stored beyond 24 hours.</p>
<p>The average daily adult dose of the resin is 15 g to 60 g. This is best provided by administering 15 g (approximately 4 <span class="Italics">level </span>teaspoons) of KAYEXALATE one to four times daily. One gram of KAYEXALATE contains 4.1 mEq of sodium; one level teaspoon contains approximately 3.5 g of KAYEXALATE and 15 mEq of sodium. (A heaping teaspoon may contain as much as 10 g to 12 g of KAYEXALATE.) Since the <span class="Italics">in vivo</span> efficiency of sodium-potassium exchange resins is approximately 33 percent, about one third of the resin's actual sodium content is being delivered to the body.</p>
<p>In smaller children and infants, lower doses should be employed by using as a guide a rate of 1 mEq of potassium per gram of resin as the basis for calculation.</p>
<p>Each dose should be given as a suspension in a small quantity of water or, for greater palatability, in syrup. The amount of fluid usually ranges from 20 mL to 100 mL, depending on the dose, or may be simply determined by allowing 3 mL to 4 mL per gram of resin. Healthcare professionals should follow full <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> precautions when administering this product, such as placing and maintaining the patient in an upright position while the resin is being administered.</p>
<p>The resin may be introduced into the stomach through a plastic tube and, if desired, mixed with a diet appropriate for a patient in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.</p>
<p>The resin may also be given, although with less effective results, in an enema consisting (for adults) of 30 g to 50 g every six hours. Each dose is administered as a warm emulsion (at body temperature) in 100 mL of aqueous vehicle. The emulsion should be <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> gently during administration. The enema should be retained as long as possible and followed by a cleansing enema.</p>
<p>After an initial cleansing enema, a soft, large size (French 28) rubber tube is inserted into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and taped in place. The resin is then suspended in the appropriate amount of aqueous vehicle at body temperature and introduced by gravity, while the particles are kept in suspension by stirring. The suspension is <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with 50 mL or 100 mL of fluid, following which the tube is clamped and left in place. If back leakage occurs, the hips are elevated on pillows or a knee-chest position is taken temporarily. A somewhat thicker suspension may be used, but care should be taken that no paste is formed, because the latter has a greatly reduced exchange surface and will be particularly ineffective if deposited in the rectal ampulla. The suspension is kept in the sigmoid colon for several hours, if possible. Then, the colon is irrigated with nonsodium containing solution at body temperature in order to remove the resin. Two quarts of <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> solution may be necessary. The returns are drained constantly through a Y tube connection. While the use of sorbitol is not recommended, particular attention should be paid to this cleansing enema if sorbitol has been used.</p>
<p>The intensity and duration of therapy depend upon the severity and resistance of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.</p>
<p>KAYEXALATE should not be heated for to do so may alter the exchange properties of the resin.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_9ac3a673-96e7-4d52-91d4-811192f922bb"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">KAYEXALATE is available as a cream to light brown, finely ground powder in jars of 1 pound (453.6 g), NDC 24987-075-01.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_9b490b66-79ef-46ba-b5f4-262ed2ff4668"></a><a name="section-10.1"></a><p></p>
<p class="First">Store at 25° C (77° F); excursions permitted to 15° – 30° C (59° – 86° F) [see USP Controlled Room Temperature]</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_676d409c-f9ca-4ce0-9494-7c5c766701ae"></a><a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
<p>Distributed by<br>Covis Pharmaceuticals, Inc.<br>Cary, NC 27511</p>
<p>© 2013 Covis Pharmaceuticals, Inc. All rights reserved.</p>
<p>Revised April 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b67c953c-309f-40c5-bdbb-ef3995eec9f2"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 453.6 g Jar</h1>
<p class="First">NDC 24987-075-01         K-450           <span class="Bold">Rx only</span></p>
<p><span class="Bold">Kayexalate</span><span class="Sup">®</span><br><span class="Bold">sodium polystyrene</span><br><span class="Bold">sulfonate, USP</span></p>
<p>                                          Read package insert.</p>
<p>Average adult dose:  15 g (approximately 4 <span class="Underline">level</span><br>teaspoons) one to four time daily in water.  See <br>complete prescribing information.</p>
<p>The effect must be carefully controlled by frequent <br>serum potassium determinations within each 24 hour <br>period. Sodium content approximately 60 mEq per 15 g.</p>
<p>Suspension should be freshly prepared and not <br>stored beyond 24 hours. dispense in tight, light-<br>resistant containers as defined in the official <br>compendia.</p>
<p>Store at 25°C (77°F); excursions permitted to <br>15°–30°C (59°–86°F) [see USP Controlled Room <br>Temperature].</p>
<p>Mfd. for: Covis Pharmaceuticals, Inc., Cary, NC 27511<br>Origin Canada   © 2013 Covis Pharmaceuticals, Inc.<br>100111        Rev. 4/13</p>
<div class="Figure"><img alt="Jar Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e7808d28-9d96-4dde-81bc-5c8357cba004&amp;name=40362e20-dfbf-4367-aae4-49b6292c57d6-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KAYEXALATE 		
					</strong><br><span class="contentTableReg">sodium polystyrene sulfonate powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24987-075</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL, RECTAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SODIUM POLYSTYRENE SULFONATE</strong> (POLYSTYRENE SULFONIC ACID) </td>
<td class="formItem">SODIUM CATION</td>
<td class="formItem">4.1 meq  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (cream to light brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24987-075-01</td>
<td class="formItem">453.6 g in 1 JAR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA011287</td>
<td class="formItem">07/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Covis Pharmaceuticals, Inc.
							(969968986)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>40362e20-dfbf-4367-aae4-49b6292c57d6</div>
<div>Set id: e7808d28-9d96-4dde-81bc-5c8357cba004</div>
<div>Version: 2</div>
<div>Effective Time: 20130808</div>
</div>
</div> <div class="DistributorName">Covis Pharmaceuticals, Inc.</div></p>
</body></html>
